Novartis Can Meet Growing Demand for Gene Therapy: CEO

The video discusses overcoming manufacturing challenges in gene therapies, expanding global manufacturing capabilities, and ensuring patient access through reimbursement. It highlights emerging medical assets, including partnerships for cardiovascular and kidney diseases. The strategy for the Sandoz generics unit is outlined, focusing on growth and market positioning. Environmental commitments, including carbon neutrality and drug disposal, are also addressed.

What environmental commitments has the company made?

What challenges are associated with the disposal of medicines?